Skip to content

Dosing errors: mg, mL and units

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

Your instructions give the dose in

Runs in your browser. What you enter stays on your device.

How this works

Pick the device you have and the unit your instructions use. The explainer tells you what that unit means for that device, based on its FDA label. It also points out the combinations that mean you should stop and call the pharmacy.

  • mg is the dose. mL and units are amounts of liquid.
  • FDA-approved pens and single-dose vials are labeled with their strength in milligrams, so there is no math to do.
  • Compounded vials have no FDA label and no standard concentration. You can only turn milligrams into units or milliliters with the concentration printed on your own vial. That is what the semaglutide and tirzepatide dosage calculators on this site ask for. If your vial doesn't show it, ask the pharmacy that gave it to you.

Instructions written in units

  • Compounded semaglutide instructions may give the dose in 'units', and the volume a unit dose represents may vary with the product's concentration.
  • Concentrations vary between compounders, and one compounder may offer several concentrations.
  • Compounded semaglutide is supplied in various containers, including multiple-dose vials and prefilled syringes.
  • Some patients were given syringes much larger than the prescribed volume.
  • FDA-approved injectable semaglutide is dosed in milligrams, has standard concentrations and comes only in pre-filled pens.

FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

Doses beyond the label

  • FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide.
  • The errors came from patients measuring and self-administering incorrect doses and, in some cases, health care professionals miscalculating doses.
  • FDA also received reports that may be related to compounded semaglutide or tirzepatide prescribed in doses beyond the FDA-approved label: more per dose, more frequent doses, or faster titration.
  • FDA encourages patients to talk with their health care provider or compounder about how to measure and administer the intended dose of compounded semaglutide or tirzepatide.

FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Multiple-dose vials

  • Compounded drugs are not FDA approved; FDA does not review them for safety, effectiveness or quality before they are marketed.
  • FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.
  • FDA recommends discarding a multiple-dose vial within 28 days after first use, even if medication remains.
  • FDA says to always use a new, sterile needle and syringe for each dose.
  • As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and says such events are likely underreported.
  • Questions about instructions for use or the label should go to the compounder or the telehealth platform that supplied the drug.

FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

What poison centers see

  • Poison Centers report a nearly 1,500% increase in calls since 2019 related to overdose or side effects of injectable weight-loss drugs.
  • Poison Centers are most often contacted about accidental therapeutic errors with FDA-approved GLP-1 drugs, such as doses taken too close together or a higher than recommended dose.
  • With compounded products, patients report accidentally taking 10 times the recommended dose because of confusing measurement units when using a syringe.
  • The page states 22,966 GLP-1 agonist related exposure cases from 2019 to 2025, and 3,633 as of April 30, 2025. An exposure is contact with the substance and is not necessarily a poisoning or overdose.
  • For questions about GLP-1 medications and overdoses, the page says to call Poison Help at 1-800-222-1222.

America's Poison Centers: America's Poison Centers - GLP-1

Fake (counterfeit) pens

  • In the 12/5/2025 update, FDA said it seized dozens of units of counterfeit Ozempic 1 mg injection labeled with lot number PAR1229, which is also an authentic lot number.
  • On the counterfeit pen the EXP/LOT text sits to the left of the expiration date and lot number; on the authentic pen it sits above them.
  • Earlier updates named lot PAR0362 with serial numbers starting 51746517 (4/14/2025) and lot NAR0074 with serial number 430834149057 (12/21/2023).
  • In the 2023 seizure the needles were counterfeit, so their sterility could not be confirmed.
  • FDA says patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for signs of counterfeiting before use.

FDA: FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain

"Research use only" products

  • FDA has warned companies selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled 'for research purposes' or 'not for human consumption'.
  • FDA urges consumers not to buy these products, which are of unknown quality and may be harmful.
  • Semaglutide salt forms (semaglutide sodium, semaglutide acetate) are different active ingredients than those in the approved drugs.
  • FDA says retatrutide and cagrilintide cannot be used in compounding under federal law.
  • FDA recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration.

FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Who to call

  • Poison Help: 1-800-222-1222, or online at PoisonHelp.org. Confidential.
  • Emergency: call 911 for trouble breathing, collapse, passing out or a seizure.
  • Report to FDA: MedWatch online form, or FDA's information line at 1-888-463-6332.
  • Your pharmacy or prescriber: for any question about how to measure or give your dose, before you give it.

Frequently asked questions

What is the difference between mg, mL and units?

Milligrams (mg) measure the amount of medicine. That is the dose. Milliliters (mL) measure the amount of liquid. Units are the markings on an insulin syringe, and they measure liquid too: on a U-100 syringe, 100 units is 1 mL. How many milligrams are in a milliliter depends on how strong the product is, so an amount of liquid only tells you the dose once you know the concentration.

Source

What dosing errors has FDA reported with compounded semaglutide?

FDA received reports of adverse events, some requiring hospitalization, that may be related to overdoses from dosing errors with compounded injectable semaglutide. Most reports involved patients drawing up too much from a multiple-dose vial; these patients took five to 20 times the intended dose. Confusion between milliliters, milligrams and 'units' may have contributed, along with unfamiliarity with drawing medication from a vial into a syringe. Some patients told to take 5 units (0.05 mL) with a U-100 insulin syringe took 50 units instead. Some health care providers miscalculated when converting milligrams to units or milliliters, leading to doses five to 10 times higher than intended. FDA encourages patients to ask their provider or compounder how to measure the intended dose, and encourages providers and compounders to supply an appropriately sized syringe and counsel patients on measuring the dose. FDA text: "The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe."

Source

Why are "units" a problem on compounded GLP-1 instructions?

Compounded semaglutide instructions may give the dose in 'units', and the volume a unit dose represents may vary with the product's concentration. Concentrations vary between compounders, and one compounder may offer several concentrations. Compounded semaglutide is supplied in various containers, including multiple-dose vials and prefilled syringes. Some patients were given syringes much larger than the prescribed volume. FDA-approved injectable semaglutide is dosed in milligrams, has standard concentrations and comes only in pre-filled pens. FDA text: "Additionally, the instructions that accompany the compounded drug, if provided, may instruct users to administer semaglutide injections in “units” (the volume of which may vary depending on the concentration), rather than milligrams or milliliters. FDA is aware of some instances in which patients have been given syringes that are significantly larger than the prescribed volume of semaglutide (see example in Figure 1)."

Source

How common are GLP-1 dosing mistakes?

Poison Centers report a nearly 1,500% increase in calls since 2019 related to overdose or side effects of injectable weight-loss drugs. Poison Centers are most often contacted about accidental therapeutic errors with FDA-approved GLP-1 drugs, such as doses taken too close together or a higher than recommended dose. With compounded products, patients report accidentally taking 10 times the recommended dose because of confusing measurement units when using a syringe. The page states 22,966 GLP-1 agonist related exposure cases from 2019 to 2025, and 3,633 as of April 30, 2025. An exposure is contact with the substance and is not necessarily a poisoning or overdose. For questions about GLP-1 medications and overdoses, the page says to call Poison Help at 1-800-222-1222. Source text: "Poison Centers are most often contacted about accidental therapeutic errors to FDA- approved GLP-1 drugs. Common mistakes include taking doses too closely together or taking a higher than recommended dose at once. With compounded products, patients report accidentally taking 10-times the recommended dose due to confusing measurement units while using a syringe."

Source

What should I do if I think I took too much?

Poison Help is reachable by phone at 1-800-222-1222 to speak with a live poison expert. Online poison help is available at https://www.poisonhelp.org/help. The service is described as fast, free and confidential. The page says to call 911 right away if a person is having difficulty breathing, collapses or is losing consciousness, or has a seizure.

Source

How do I report a dosing problem or a bad product?

MedWatch takes reports of serious reactions, product quality problems and product use errors with human medical products, including drugs. Patients and consumers can complete the online reporting form themselves; a health care provider is not required. FDA's toll-free information line is 1-888-INFO-FDA (1-888-463-6332); press 2 to report into MedWatch or for instructions. A consumer-friendly paper form (Form FDA 3500B) is available at https://www.fda.gov/media/85598/download.

Source

How long can a multiple-dose vial be used?

FDA recommends discarding a multiple-dose vial within 28 days after first use, even if medication remains. FDA says to always use a new, sterile needle and syringe for each dose. FDA text: "Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days. Always use a new, sterile needle and syringe for each dose. Reusing needles or syringes can result in contamination of the medication."

Source

How do I spot counterfeit Ozempic?

In the 12/5/2025 update, FDA said it seized dozens of units of counterfeit Ozempic 1 mg injection labeled with lot number PAR1229, which is also an authentic lot number. On the counterfeit pen the EXP/LOT text sits to the left of the expiration date and lot number; on the authentic pen it sits above them. Earlier updates named lot PAR0362 with serial numbers starting 51746517 (4/14/2025) and lot NAR0074 with serial number 430834149057 (12/21/2023). In the 2023 seizure the needles were counterfeit, so their sterility could not be confirmed. FDA says patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for signs of counterfeiting before use.

Source

Sources (14)

  1. 1.
    America's Poison Centers: America's Poison Centers - GLP-1
    “Poison Centers are most often contacted about accidental therapeutic errors to FDA- approved GLP-1 drugs. Common mistakes include taking doses too closely together or taking a higher than recommended dose at once. With compounded products, patients report accidentally taking 10-times the recommended dose due to confusing measurement units while using a syringe.”
  2. 2.
    America's Poison Centers: America's Poison Centers
    “America’s Poison Centers® represents the 53 accredited poison control centers in the U.S. Through the national Poison Help line (1-800-222-1222) and PoisonHelp.org website, our member centers provide all Americans expert advice, 24/7/365 at no cost.”
  3. 3.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA encourages health care professionals, patients and compounders to report adverse events or quality problems with these or any medications to FDA’s MedWatch Adverse Event Reporting program: Complete and submit the report online, or Download and complete the form, then submit it via fax at 1-800-FDA-0178. You also may contact the CDER Office of Drug Information at druginfo@fda.hhs.gov or 855-543-3784.”
  4. 4.
    FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
    “The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.”
  5. 5.
    FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
    “Additionally, the instructions that accompany the compounded drug, if provided, may instruct users to administer semaglutide injections in “units” (the volume of which may vary depending on the concentration), rather than milligrams or milliliters. FDA is aware of some instances in which patients have been given syringes that are significantly larger than the prescribed volume of semaglutide (see example in Figure 1).”
  6. 6.
    FDA: FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain
    “The counterfeit products labeled with lot number PAR1229 can be identified by the location of the EXP/LOT text on the pen's label. The counterfeit product has the EXP/LOT text on the left side of the expiration date and lot number, while the authentic Ozempic pen contains the EXP/LOT text above the expiration date and lot number.”
  7. 7.
    FDA: MedWatch: The FDA Safety Information and Adverse Event Reporting Program
    “MedWatch, the FDA’s medical product safety reporting program for health professionals, patients and consumers.”
  8. 8.
    FDA: Reporting Serious Problems to FDA
    “MedWatch is the Food and Drug Administration's (FDA) program for reporting serious reactions, product quality problems, therapeutic inequivalence/failure, and product use errors with human medical products, including drugs, biologic products, medical devices, dietary supplements, infant formula, and cosmetics.”
  9. 9.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA is aware of counterfeit Ozempic marketed in the U.S. Counterfeit drugs claim to be authentic, but could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal.”
  10. 10.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.”
  11. 11.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days. Always use a new, sterile needle and syringe for each dose. Reusing needles or syringes can result in contamination of the medication.”
  12. 12.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”
  13. 13.
    America's Poison Centers: Poison Control | Call Poison Help Centers Now 1-800-222-1222
    “If you think someone has been poisoned, use PoisonHelp.org or call Poison Help at 1-800-222-1222 right away.”
  14. 14.
    National Capital Poison Center (poison.org): Poison Control | Your trusted resource
    “Use the webPOISONCONTROL online tool, or call a poison center at 1-800-222-1222. Both options are free, expert, and confidential.”